<SEC-DOCUMENT>0001140361-23-044652.txt : 20230920
<SEC-HEADER>0001140361-23-044652.hdr.sgml : 20230920
<ACCEPTANCE-DATETIME>20230920213148
ACCESSION NUMBER:		0001140361-23-044652
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20230918
FILED AS OF DATE:		20230920
DATE AS OF CHANGE:		20230920

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Oren Ilan
		CENTRAL INDEX KEY:			0001643073

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40782
		FILM NUMBER:		231267641

	MAIL ADDRESS:	
		STREET 1:		C/O AXOVANT SCIENCES, INC.
		STREET 2:		1441 BROADWAY, 3RD FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10018

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Roivant Sciences Ltd.
		CENTRAL INDEX KEY:			0001635088
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				981173944
		STATE OF INCORPORATION:			D0
		FISCAL YEAR END:			0331

	BUSINESS ADDRESS:	
		STREET 1:		CLARENDON HOUSE, 2 CHURCH STREET
		CITY:			HAMILTON HM11
		STATE:			D0
		ZIP:			HM11
		BUSINESS PHONE:		441-295-5950

	MAIL ADDRESS:	
		STREET 1:		CLARENDON HOUSE
		STREET 2:		2 CHURCH STREET
		CITY:			HAMILTON
		STATE:			D0
		ZIP:			HM11
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>form4.xml
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0508</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2023-09-18</periodOfReport>

    <issuer>
        <issuerCik>0001635088</issuerCik>
        <issuerName>Roivant Sciences Ltd.</issuerName>
        <issuerTradingSymbol>ROIV</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001643073</rptOwnerCik>
            <rptOwnerName>Oren Ilan</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O ROIVANT SCIENCES LTD.</rptOwnerStreet1>
            <rptOwnerStreet2>7TH FLOOR, 50 BROADWAY</rptOwnerStreet2>
            <rptOwnerCity>LONDON</rptOwnerCity>
            <rptOwnerState>X0</rptOwnerState>
            <rptOwnerZipCode>SW1H 0DB</rptOwnerZipCode>
            <rptOwnerStateDescription>UNITED KINGDOM</rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>true</isDirector>
        </reportingOwnerRelationship>
    </reportingOwner>

    <aff10b5One>false</aff10b5One>

    <nonDerivativeTable>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Common Shares</value>
            </securityTitle>
            <transactionDate>
                <value>2023-09-18</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>J</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>8703</value>
                    <footnoteId id="F1"/>
                </transactionShares>
                <transactionPricePerShare>
                    <value>11.17</value>
                    <footnoteId id="F2"/>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>D</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>72707</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
    </nonDerivativeTable>

    <footnotes>
        <footnote id="F1">Represents the sale of Common Shares pursuant to a &quot;sell-to-cover&quot; transaction in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of restricted stock units (&quot;RSUs&quot;) previously granted to the reporting person. This sale was effected pursuant to a &quot;sell to cover&quot; policy entered into pursuant to the requirements of Rule 10b5-1 and does not represent a discretionary sale by the reporting person.</footnote>
        <footnote id="F2">The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (2) to this Form 4</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>By: /s/ Jo Chen, as Attorney-in-Fact for Ilan Oren</signatureName>
        <signatureDate>2023-09-20</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
